NO301168B1 - Fremgangsmåte for fremstilling av et konjugat av et antistoff rettet mot antigen - Google Patents

Fremgangsmåte for fremstilling av et konjugat av et antistoff rettet mot antigen Download PDF

Info

Publication number: NO301168B1
Authority: NO; Norway
Prior art keywords: tnf; cells; antibody; antigen; tumor
Prior art date: 1989-05-05

Application number

NO901986A

Other languages

English (en)

Norwegian (no)

Other versions

NO901986L (no

NO901986D0 (no

Inventor

Michael G Rosenblum

Clyde William Wellen

Original Assignee

Res Dev Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-05-05

Filing date

1990-05-04

Publication date

1997-09-22

1990-05-04 Application filed by Res Dev Foundation filed Critical Res Dev Foundation

1990-05-04 Publication of NO901986D0 publication Critical patent/NO901986D0/no

1990-11-06 Publication of NO901986L publication Critical patent/NO901986L/no

1997-09-22 Publication of NO301168B1 publication Critical patent/NO301168B1/no

Links

239000000427 antigen Substances 0.000 title claims description 74
108091007433 antigens Proteins 0.000 title claims description 74
102000036639 antigens Human genes 0.000 title claims description 74
238000004519 manufacturing process Methods 0.000 title claims description 4
210000004027 cell Anatomy 0.000 claims description 122
102100040247 Tumor necrosis factor Human genes 0.000 claims description 86
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 85
201000001441 melanoma Diseases 0.000 claims description 17
208000026310 Breast neoplasm Diseases 0.000 claims description 14
206010006187 Breast cancer Diseases 0.000 claims description 13
239000000126 substance Substances 0.000 claims description 4
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
230000004927 fusion Effects 0.000 claims description 2
230000002068 genetic effect Effects 0.000 claims 1
238000000034 method Methods 0.000 abstract description 20
239000000367 immunologic factor Substances 0.000 abstract description 6
201000010099 disease Diseases 0.000 abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
102000004127 Cytokines Human genes 0.000 abstract description 3
108090000695 Cytokines Proteins 0.000 abstract description 3
230000004044 response Effects 0.000 abstract description 3
-1 for example Proteins 0.000 abstract description 2
239000003607 modifier Substances 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 description 48
210000004881 tumor cell Anatomy 0.000 description 33
239000003795 chemical substances by application Substances 0.000 description 31
229940127121 immunoconjugate Drugs 0.000 description 26
230000000694 effects Effects 0.000 description 24
150000001875 compounds Chemical class 0.000 description 19
241000282414 Homo sapiens Species 0.000 description 17
108090000623 proteins and genes Proteins 0.000 description 16
230000008512 biological response Effects 0.000 description 14
102000004169 proteins and genes Human genes 0.000 description 14
201000011510 cancer Diseases 0.000 description 13
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
239000002953 phosphate buffered saline Substances 0.000 description 13
230000001472 cytotoxic effect Effects 0.000 description 11
229940079593 drug Drugs 0.000 description 11
239000003814 drug Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000002596 immunotoxin Substances 0.000 description 10
229940051026 immunotoxin Drugs 0.000 description 10
230000002637 immunotoxin Effects 0.000 description 10
231100000608 immunotoxin Toxicity 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
230000000890 antigenic effect Effects 0.000 description 9
231100000433 cytotoxic Toxicity 0.000 description 9
239000003053 toxin Substances 0.000 description 9
231100000765 toxin Toxicity 0.000 description 9
108700012359 toxins Proteins 0.000 description 9
238000010828 elution Methods 0.000 description 8
210000004408 hybridoma Anatomy 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
238000011282 treatment Methods 0.000 description 8
230000004071 biological effect Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 7
102000014150 Interferons Human genes 0.000 description 6
108010050904 Interferons Proteins 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
241001529936 Murinae Species 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
229920005654 Sephadex Polymers 0.000 description 5
239000012507 Sephadex™ Substances 0.000 description 5
230000001028 anti-proliverative effect Effects 0.000 description 5
238000003556 assay Methods 0.000 description 5
230000021615 conjugation Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
229940079322 interferon Drugs 0.000 description 5
230000004060 metabolic process Effects 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
238000002835 absorbance Methods 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000010261 cell growth Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000000824 cytostatic agent Substances 0.000 description 4
230000001085 cytostatic effect Effects 0.000 description 4
231100000599 cytotoxic agent Toxicity 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
230000003013 cytotoxicity Effects 0.000 description 4
231100000135 cytotoxicity Toxicity 0.000 description 4
230000008030 elimination Effects 0.000 description 4
238000003379 elimination reaction Methods 0.000 description 4
210000002950 fibroblast Anatomy 0.000 description 4
239000000499 gel Substances 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000011534 wash buffer Substances 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
206010005003 Bladder cancer Diseases 0.000 description 3
108700004714 Gelonium multiflorum GEL Proteins 0.000 description 3
108090000467 Interferon-beta Proteins 0.000 description 3
108010002352 Interleukin-1 Proteins 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
230000000975 bioactive effect Effects 0.000 description 3
201000001531 bladder carcinoma Diseases 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
230000022534 cell killing Effects 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000001086 cytosolic effect Effects 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
239000003550 marker Substances 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
239000011550 stock solution Substances 0.000 description 3
230000008685 targeting Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
208000010570 urinary bladder carcinoma Diseases 0.000 description 3
238000011725 BALB/c mouse Methods 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102100026720 Interferon beta Human genes 0.000 description 2
108010074338 Lymphokines Proteins 0.000 description 2
102000008072 Lymphokines Human genes 0.000 description 2
102000007557 Melanoma-Specific Antigens Human genes 0.000 description 2
108010071463 Melanoma-Specific Antigens Proteins 0.000 description 2
101710160107 Outer membrane protein A Proteins 0.000 description 2
108010039491 Ricin Proteins 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
208000019065 cervical carcinoma Diseases 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
230000001066 destructive effect Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000013024 dilution buffer Substances 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
210000004754 hybrid cell Anatomy 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000000984 immunochemical effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000011068 loading method Methods 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
GJMPSRSMBJLKKB-UHFFFAOYSA-N 3-methylphenylacetic acid Chemical compound CC1=CC=CC(CC(O)=O)=C1 GJMPSRSMBJLKKB-UHFFFAOYSA-N 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
208000000571 Fibrocystic breast disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000577979 Peromyscus spicilegus Species 0.000 description 1
231100000742 Plant toxin Toxicity 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
206010060862 Prostate cancer Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
206010054094 Tumour necrosis Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
230000002942 anti-growth Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
230000024279 bone resorption Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
208000011803 breast fibrocystic disease Diseases 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000007821 culture assay Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
231100000409 cytocidal Toxicity 0.000 description 1
230000000445 cytocidal effect Effects 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
239000012154 double-distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000012636 effector Substances 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
230000009422 growth inhibiting effect Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
102000057041 human TNF Human genes 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
238000011328 necessary treatment Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000004882 non-tumor cell Anatomy 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002947 procoagulating effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
210000000512 proximal kidney tubule Anatomy 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000007447 staining method Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
238000012090 tissue culture technique Methods 0.000 description 1
RUELTTOHQODFPA-UHFFFAOYSA-N toluene 2,6-diisocyanate Chemical compound CC1=C(N=C=O)C=CC=C1N=C=O RUELTTOHQODFPA-UHFFFAOYSA-N 0.000 description 1
231100000167 toxic agent Toxicity 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000014616 translation Effects 0.000 description 1
229940117957 triethanolamine hydrochloride Drugs 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000011800 void material Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Ophthalmology & Optometry (AREA)
Microbiology (AREA)
Mycology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Materials For Medical Uses (AREA)

NO901986A 1989-05-05 1990-05-04 Fremgangsmåte for fremstilling av et konjugat av et antistoff rettet mot antigen NO301168B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US34823789A	1989-05-05	1989-05-05

Publications (3)

Publication Number	Publication Date
NO901986D0 NO901986D0 (no)	1990-05-04
NO901986L NO901986L (no)	1990-11-06
NO301168B1 true NO301168B1 (no)	1997-09-22

Family

ID=23367161

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO901986A NO301168B1 (no)	1989-05-05	1990-05-04	Fremgangsmåte for fremstilling av et konjugat av et antistoff rettet mot antigen

Country Status (19)

Country	Link
EP (1)	EP0396387B1 (ja)
JP (1)	JP3589459B2 (ja)
KR (1)	KR0181294B1 (ja)
CN (1)	CN1072505C (ja)
AT (1)	ATE98873T1 (ja)
AU (1)	AU645747B2 (ja)
CA (1)	CA2015060C (ja)
DE (1)	DE69005352T2 (ja)
DK (1)	DK0396387T3 (ja)
ES (1)	ES2060947T3 (ja)
FI (1)	FI100092B (ja)
HK (1)	HK1006678A1 (ja)
IE (1)	IE63847B1 (ja)
IL (1)	IL94167A (ja)
NO (1)	NO301168B1 (ja)
NZ (1)	NZ233413A (ja)
PT (1)	PT93966B (ja)
SA (1)	SA90110099B1 (ja)
ZA (1)	ZA902949B (ja)

Families Citing this family (190)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0406857B1 (en) *	1989-07-07	1995-05-24	Takeda Chemical Industries, Ltd.	Proteins and production thereof
US5314995A (en) *	1990-01-22	1994-05-24	Oncogen	Therapeutic interleukin-2-antibody based fusion proteins
ATE106251T1 (de) *	1990-02-06	1994-06-15	Takeda Chemical Industries Ltd	Immunkomplexe.
IL97776A (en) *	1990-04-19	2000-10-31	Res Dev Foundation	Composition comprising a conjugate of a ZME antibody and a biological response modifier
US5349053A (en) *	1990-06-01	1994-09-20	Protein Design Labs, Inc.	Chimeric ligand/immunoglobulin molecules and their uses
US5273889A (en) *	1990-08-22	1993-12-28	University Of Saskatchewan	Gamma-iterferon-leukotoxin gene fusions and uses thereof
US5594107A (en) *	1990-08-22	1997-01-14	University Of Saskatchewan	Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon
JPH06502301A (ja) *	1990-08-29	1994-03-17	サントル　オスピタリエ　レジオナル　デ　ナント	安定タンパク質コアに結合されたタンパク質ポリリガンド
US5650150A (en) *	1990-11-09	1997-07-22	Gillies; Stephen D.	Recombinant antibody cytokine fusion proteins
JPH09506761A (ja) *	1990-11-09	1997-07-08	ステファンディー．ギリーズ	サイトカインの免疫複合体
WO1992008801A1 (en) *	1990-11-09	1992-05-29	Abbott Laboratories	Bridging antibody fusion constructs
EP0721340A1 (en) *	1991-03-07	1996-07-17	Seragen, Inc.	Use of cell surface receptor targeted molecules for the treatment of viral diseases
JP3105629B2 (ja) *	1991-04-23	2000-11-06	サングスタットメディカルコーポレイション	特異的結合ペアのメンバーの細胞活性調節接合体
US5326559A (en) *	1991-05-16	1994-07-05	Miller D Douglas	Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
ATE168014T1 (de) *	1991-11-08	1998-07-15	Somatogen Inc	Hämoglobine als arzneimittelabgabesystem
GB9324807D0 (en) *	1993-12-03	1994-01-19	Cancer Res Campaign Tech	Tumour antibody
DK0659439T3 (da) *	1993-12-24	2002-01-14	Merck Patent Gmbh	Immunkonjugater
GB9415379D0 (en) *	1994-07-29	1994-09-21	Smithkline Beecham Plc	Novel compounds
DE69523857T2 (de) *	1994-09-16	2002-06-13	Merck Patent Gmbh	Immunokonjugate
US7820798B2 (en)	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US6090382A (en) *	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US6482927B1 (en) *	1995-11-27	2002-11-19	Millennium Pharmaceuticals, Inc.	Chimeric proteins comprising the extracellular domain of murine Ob receptor
US6620413B1 (en)	1995-12-27	2003-09-16	Genentech, Inc.	OB protein-polymer chimeras
US6541604B1 (en)	1996-01-08	2003-04-01	Genentech, Inc.	Leptin receptor having a WSX motif
US20050019325A1 (en)	1996-01-08	2005-01-27	Carter Paul J.	WSX receptor agonist antibodies
US7074397B1 (en)	1996-01-08	2006-07-11	Genentech, Inc.	Method for enhancing proliferation or differentiation of a cell using ob protein
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
SI9720020B (en) *	1996-02-09	2001-12-31	Basf Ag	Human antibodies that bind human TNF alpha
EP1489100B1 (en)	1997-12-08	2016-06-15	Merck Patent GmbH	Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
EP1093457B8 (en)	1998-03-19	2011-02-02	Human Genome Sciences, Inc.	Cytokine receptor common gamma chain like
CA2363779A1 (en)	1999-02-26	2000-08-31	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja)	1999-08-09	2011-10-12	メルクパテントゲーエムベーハー	複合サイトカイン−抗体複合体
MXPA02007733A (es)	2000-02-11	2004-09-10	Merck Patent Gmbh	Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en)	2000-06-15	2001-12-24	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
ES2609016T3 (es)	2000-06-16	2017-04-18	Human Genome Sciences, Inc.	Anticuerpos que se unen inmunoespecíficamente a BLyS
EP1292334A4 (en) *	2000-06-22	2003-11-19	Idec Pharma Corp	BISPECIFIC FUSION PROTEIN AND METHOD FOR USE TO ENHANCE THE KILLING OF TARGET CELLS BY EFFECTOR CELLS
AU1994402A (en)	2000-11-28	2002-06-11	Mediummune Inc	Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
EP1366058B1 (en)	2001-02-09	2011-01-26	Human Genome Sciences, Inc.	Human g-protein chemokine receptor (ccr5) hdgnr10
ZA200305980B (en)	2001-02-12	2007-01-31	Res Dev Foundation	Modified proteins, designer toxins, and methods of making thereof
US7148321B2 (en)	2001-03-07	2006-12-12	Emd Lexigen Research Center Corp.	Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en)	2001-03-30	2006-01-31	Emd Lexigen Research Center Corp.	Reducing the immunogenicity of fusion proteins
US7208582B2 (en)	2001-04-13	2007-04-24	Human Genome Sciences, Inc.	Vascular endothelial growth factor 2
US6969517B2 (en)	2001-05-03	2005-11-29	Emd Lexigen Research Center Corp.	Recombinant tumor specific antibody and use thereof
ES2437992T3 (es)	2001-05-25	2014-01-15	Human Genome Sciences, Inc.	Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
AU2002327310B2 (en)	2001-07-17	2006-09-28	Research Development Foundation	Therapeutic agents comprising pro-apoptotic proteins
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
CN100390282C (zh)	2001-12-04	2008-05-28	默克专利有限公司	具有调节的选择性的il-2融合蛋白
EP1499352A4 (en)	2002-04-12	2006-10-11	Medimmune Inc	ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
GB0209896D0 (en)	2002-04-30	2002-06-05	Molmed Spa	Conjugate
EP1531848A4 (en)	2002-06-10	2007-03-28	Vaccinex Inc	DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE
US7232888B2 (en)	2002-07-01	2007-06-19	Massachusetts Institute Of Technology	Antibodies against tumor surface antigens
PT1572748E (pt)	2002-12-17	2010-09-28	Merck Patent Gmbh	Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
DK2248899T3 (en)	2003-03-19	2015-06-29	Biogen Ma Inc	Nogo receptor-binding protein
EP2266628A3 (en)	2003-05-13	2012-01-18	Novartis Vaccines and Diagnostics, Inc.	Method of determining the susceptibility to bone meatastases by EPhA2 expression
SI1703893T1 (sl)	2003-12-23	2012-07-31	Genentech Inc	Nova protitelesa proti il in uporaba le teh
AU2004309050B2 (en)	2003-12-30	2010-10-14	Merck Patent Gmbh	IL-7 fusion proteins
AU2005203962C1 (en)	2004-01-05	2012-11-08	Antisoma Research Limited	Interleukin-12 targeted to oncofoetal fibronectin
EP1776136B1 (en)	2004-06-24	2012-10-03	Biogen Idec MA Inc.	Treatment of conditions involving demyelination
US7670595B2 (en)	2004-06-28	2010-03-02	Merck Patent Gmbh	Fc-interferon-beta fusion proteins
KR20070037719A (ko) *	2004-06-30	2007-04-06	노파르티스 아게	항종양제로서의 항체와 듀오카르마이신 유도체의컨쥬게이트
WO2006017673A2 (en)	2004-08-03	2006-02-16	Biogen Idec Ma Inc.	Taj in neuronal function
WO2006078776A2 (en)	2005-01-19	2006-07-27	The Trustees Of The University Of Pennsylvania	Inhibitors and methods of treatment of cardiovascular diseases, and methods for identifying inhibitors
WO2007002543A2 (en)	2005-06-23	2007-01-04	Medimmune, Inc.	Antibody formulations having optimized aggregation and fragmentation profiles
SG163591A1 (en)	2005-07-08	2010-08-30	Biogen Idec Inc	Sp35 antibodies and uses thereof
EP1904652A2 (en)	2005-07-08	2008-04-02	Brystol-Myers Squibb Company	Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
EP2500030B2 (en)	2005-11-04	2018-08-08	Genentech, Inc.	Use of complement pathway inhibitors to treat ocular diseases
AU2006311828B2 (en)	2005-11-04	2013-07-11	Biogen Ma Inc.	Methods for promoting neurite outgrowth and survival of dopaminergic neurons
EP1945261A4 (en)	2005-11-07	2010-05-12	Scripps Research Inst	COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
JP5312039B2 (ja)	2005-12-02	2013-10-09	バイオジェン・アイデック・エムエイ・インコーポレイテッド	脱髄の関与する状態の処置
PT1981902E (pt)	2006-01-27	2015-11-02	Biogen Ma Inc	Antagonistas dos recetores nogo
TW200813231A (en)	2006-04-13	2008-03-16	Novartis Vaccines & Diagnostic	Methods of treating, diagnosing or detecting cancer
SG172684A1 (en)	2006-06-07	2011-07-28	Bioalliance Cv	Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
RS53120B (en)	2006-08-28	2014-06-30	Kyowa Hakko Kirin Co. Ltd.	ANTAGONISTIC HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE HUMAN LIGHT
US9382327B2 (en)	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
NZ577274A (en)	2006-12-18	2012-10-26	Genentech Inc	Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
PL2099826T3 (pl)	2007-01-05	2014-04-30	Univ Zuerich	Przeciwciało przeciwko beta-amyloidowi i jego zastosowania
PT2068887E (pt)	2007-01-09	2014-06-23	Biogen Idec Inc	Anticorpos sp35 e suas utilizações
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
MX2009008178A (es)	2007-02-02	2009-10-26	Biogen Idec Inc	Uso de semaforina 6a para promover la mielinizacion y la diferenciacion de oligodendrocitos.
WO2008112988A2 (en)	2007-03-14	2008-09-18	Novartis Ag	Apcdd1 inhibitors for treating, diagnosing or detecting cancer
TW200902547A (en)	2007-04-27	2009-01-16	Genentech Inc	Potent, stable and non-immunosuppressive anti-CD4 antibodies
BRPI0815983A2 (pt)	2007-08-29	2018-05-22	Sanofi Aventis	anticorpos anti-cxcr5 humanizados, derivados dos mesmos e seus usos
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
US8236316B2 (en)	2007-11-21	2012-08-07	Oregon Health & Science University	Anti-factor XI monoclonal antibodies and methods of use thereof
RU2528738C2 (ru)	2007-12-18	2014-09-20	Биоэллаенс К.В.	Антитела, узнающие углеводсодержащий эпитоп на cd43 и сеа, экспрессируемых на раковых клетках и способы их применения
WO2009082485A1 (en)	2007-12-26	2009-07-02	Vaccinex, Inc.	Anti-c35 antibody combination therapies and methods
EP2260102A1 (en)	2008-03-25	2010-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by down-regulating frizzled-4 and/or frizzled-1
MX2010011206A (es)	2008-04-16	2010-11-12	Biogen Idec Inc	Metodo para aislar biomacromoleculas usando glicol de polialquileno y metales de transicion.
EP2315779A2 (en)	2008-07-09	2011-05-04	Biogen Idec MA Inc.	Compositions comprising antibodies to lingo or fragments thereof
ES2549877T3 (es)	2008-09-07	2015-11-02	Glyconex Inc.	Anticuerpo antiglucoesfingolípido de tipo I extendido, derivados del mismo y utilización
EP2362783A2 (en) *	2008-10-31	2011-09-07	Biogen Idec MA Inc.	Light targeting molecules and uses thereof
BRPI0923157B1 (pt)	2008-12-19	2021-12-28	University Of Zürich	Anticorpos anti-alfa-sinucleína e seus fragmentos, seus usos e método de preparação, composição compreendendo-os, bem como kit e métodos para o diagnóstico e monitoramento de uma doença sinucleinopática
US20120003235A1 (en)	2008-12-31	2012-01-05	Biogen Idec Ma Inc.	Anti-lymphotoxin antibodies
US20110311521A1 (en)	2009-03-06	2011-12-22	Pico Caroni	Novel therapy for anxiety
CN102428103B (zh)	2009-03-24	2015-04-08	泰华生物制药美国公司	抗light的人源化抗体及其使用
EP2241323A1 (en)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W and brain cancers
WO2010121766A1 (en)	2009-04-22	2010-10-28	Merck Patent Gmbh	Antibody fusion proteins with modified fcrn binding sites
JP6059013B2 (ja)	2009-05-08	2017-01-11	バクシネックスインコーポレーティッド	抗ｃｄ１００抗体およびこれを使用するための方法
MX2012001882A (es)	2009-08-13	2012-04-11	Crucell Holland Bv	Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
EP2292266A1 (en)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Treating cancer by modulating copine III
WO2011035205A2 (en)	2009-09-18	2011-03-24	Calmune Corporation	Antibodies against candida, collections thereof and methods of use
WO2011036118A1 (en)	2009-09-22	2011-03-31	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mex-3
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
AU2010315101B2 (en)	2009-11-04	2016-01-28	Fabrus Llc	Methods for affinity maturation-based antibody optimization
EP2542578A1 (en)	2010-03-05	2013-01-09	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Smoc1, tenascin-c and brain cancers
US20130034543A1 (en)	2010-04-19	2013-02-07	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear	Modulating xrn1
WO2011154485A1 (en)	2010-06-10	2011-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mammalian sterile 20-like kinase 3
SG186985A1 (en)	2010-07-09	2013-02-28	Crucell Holland Bv	Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
EP2609431B1 (en)	2010-08-27	2017-05-10	University of Zurich	Method for target and drug validation in inflammatory and/or cardiovascular diseases
JP6097690B2 (ja)	2010-09-02	2017-03-15	ヴァクシネックス，インコーポレイテッド	抗ｃｘｃｌ１３抗体およびそれを用いる方法
EP2614080A1 (en)	2010-09-10	2013-07-17	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Phosphorylated twist1 and metastasis
MX345092B (es)	2010-10-11	2017-01-17	Univ Zuerich	Anticuerpos anti-tau humanos,.
EP2640738A1 (en)	2010-11-15	2013-09-25	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Anti-fungal agents
WO2012080518A1 (en)	2010-12-17	2012-06-21	Neurimmune Holding Ag	Human anti-sod1 antibodies
AR085911A1 (es)	2011-03-16	2013-11-06	Sanofi Sa	Dosis terapeutica segura de una proteina similar a un anticuerpo con region v dual
EP2717911A1 (en)	2011-06-06	2014-04-16	Novartis Forschungsstiftung, Zweigniederlassung	Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
US9561274B2 (en)	2011-06-07	2017-02-07	University Of Hawaii	Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
LT2723379T (lt)	2011-06-23	2018-10-25	Biogen International Neuroscience Gmbh	Anti-alfa sinukleiną rišančios molekulės
WO2013034579A1 (en)	2011-09-05	2013-03-14	Rheinische Friedrich-Wilhelms-Universität Bonn	Biosynthetic gene cluster for the production of peptide/protein analogues
US20130108641A1 (en)	2011-09-14	2013-05-02	Sanofi	Anti-gitr antibodies
US9221907B2 (en)	2011-11-01	2015-12-29	Bionomics Inc.	Anti-GPR49 monoclonal antibodies
EP2773373B1 (en)	2011-11-01	2018-08-22	Bionomics, Inc.	Methods of blocking cancer stem cell growth
CA2853951A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Antibodies and methods of treating cancer
AU2012332590B2 (en)	2011-11-01	2016-10-20	Bionomics, Inc.	Anti-GPR49 antibodies
US20140314787A1 (en)	2011-11-08	2014-10-23	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Treatment for neurodegenerative diseases
US20140294732A1 (en)	2011-11-08	2014-10-02	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Early diagnostic of neurodegenerative diseases
US9416179B2 (en)	2011-12-05	2016-08-16	X-Body, Inc.	PDGF receptor beta binding polypeptides
EP2800583A1 (en)	2012-01-02	2014-11-12	Novartis AG	Cdcp1 and breast cancer
AU2013225812B2 (en)	2012-03-02	2017-11-30	Vaccinex, Inc.	Methods for the treatment of B cell-mediated inflammatory diseases
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
CA2868353C (en)	2012-03-28	2023-10-31	Sanofi	Antibodies to bradykinin b1 receptor ligands
WO2013144240A1 (en)	2012-03-29	2013-10-03	Friedrich Miescher Institute For Biomedical Research	Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
EP2847216A1 (en)	2012-05-07	2015-03-18	Sanofi	Methods for preventing biofilm formation
JP2015518829A (ja)	2012-05-14	2015-07-06	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
WO2013175276A1 (en)	2012-05-23	2013-11-28	Argen-X B.V	Il-6 binding molecules
JP5868549B2 (ja)	2012-05-24	2016-02-24	マウントゲイトグループリミテッド	狂犬病感染の予防および治療に関する組成物および方法
EP2866831A1 (en)	2012-06-29	2015-05-06	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating diseases by modulating a specific isoform of mkl1
EP2870242A1 (en)	2012-07-05	2015-05-13	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	New treatment for neurodegenerative diseases
WO2014006115A1 (en)	2012-07-06	2014-01-09	Novartis Ag	Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
MY181648A (en)	2012-08-24	2020-12-30	Univ California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CA2896066C (en)	2012-12-21	2022-07-12	Biogen Ma Inc.	Human anti-tau antibodies
JP6407165B2 (ja)	2012-12-31	2018-10-17	ニューリミューンホールディングエイジー	ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体
AU2013205589A1 (en)	2013-03-08	2014-09-25	Vaccinex, Inc.	Anti-CXCL13 antibodies and associated epitope sequences
NZ712300A (en)	2013-03-15	2020-07-31	Sutter West Bay Hospitals	Falz for use as a target for therapies to treat cancer
SG11201509982UA (ja)	2013-06-06	2016-04-28	Igenica Biotherapeutics Inc
WO2015019286A1 (en)	2013-08-07	2015-02-12	Friedrich Miescher Institute For Biomedical Research	New screening method for the treatment friedreich's ataxia
TWI592426B (zh)	2013-08-13	2017-07-21	賽諾菲公司	胞漿素原活化素抑制劑－１（ｐａｉ－１）之抗體及其用途
ES2770507T3 (es)	2013-08-13	2020-07-01	Sanofi Sa	Anticuerpos dirigidos contra el inhibidor de los activadores del plasminógeno de tipo 1 (PAI-1) y usos de los mismos
PT3060229T (pt)	2013-10-24	2021-10-07	Astrazeneca Ab	Formulações aquosas estáveis de anticorpos
US10272117B2 (en)	2014-02-24	2019-04-30	Celgene Corporation	Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
CA2943242A1 (en)	2014-03-21	2015-09-24	X-Body, Inc.	Bi-specific antigen-binding polypeptides
EP3126397B1 (en)	2014-04-04	2020-01-29	Bionomics, Inc.	Humanized antibodies that bind lgr5
EP3154579A1 (en)	2014-06-13	2017-04-19	Friedrich Miescher Institute for Biomedical Research	New treatment against influenza virus
US10308935B2 (en)	2014-06-23	2019-06-04	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
US20170165261A1 (en)	2014-07-01	2017-06-15	Brian Arthur Hemmings	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
JP2017522886A (ja)	2014-07-29	2017-08-17	ニューリミューンホールディングエイジー	ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
EP3197557A1 (en)	2014-09-24	2017-08-02	Friedrich Miescher Institute for Biomedical Research	Lats and breast cancer
CN108064248B (zh)	2014-09-30	2022-03-15	生物控股有限公司	人源抗二肽重复(dpr)抗体
JP6672293B2 (ja)	2014-10-31	2020-03-25	メディミューン，エルエルシー	改善された製造方法
NZ733055A (en)	2014-12-11	2023-03-31	Pf Medicament	Anti-c10orf54 antibodies and uses thereof
WO2016112270A1 (en)	2015-01-08	2016-07-14	Biogen Ma Inc.	Lingo-1 antagonists and uses for treatment of demyelinating disorders
PT3265123T (pt)	2015-03-03	2023-02-01	Kymab Ltd	Anticorpos, usos e métodos
BR112017020955A2 (pt)	2015-03-31	2018-07-10	Medimmune Limited	forma de il33, formas mutadas de il33, anticorpos, ensaios e métodos de uso dos mesmos
WO2017048902A1 (en)	2015-09-15	2017-03-23	Board Of Regents, The University Of Texas System	T-cell receptor (tcr)-binding antibodies and uses thereof
EP3368566A1 (en)	2015-10-28	2018-09-05	Friedrich Miescher Institute for Biomedical Research	Tenascin-w and biliary tract cancers
CA3010601A1 (en)	2016-01-08	2017-07-13	Bioalliance C.V.	Tetravalent anti-psgl-1 antibodies and uses thereof
BR112018067951A2 (pt)	2016-03-10	2019-02-05	Viela Bio Inc	moléculas que se ligam a ilt7 e métodos de uso destas
JP2019509322A (ja)	2016-03-22	2019-04-04	バイオノミクスリミテッド	抗ｌｇｒ５モノクローナル抗体の投与
JP2018035137A (ja)	2016-07-13	2018-03-08	マブイミューンダイアグノスティックスエイジーＭａｂｉｍｍｕｎｅＤｉａｇｎｏｓｔｉｃｓＡｇ	新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102680924B1 (ko)	2017-05-05	2024-07-02	백시넥스 인코포레이티드	인간 항-세마포린 4d 항체
WO2019094595A2 (en)	2017-11-09	2019-05-16	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
MX2020005473A (es)	2017-11-27	2020-08-27	Purdue Pharma Lp	Anticuerpos humanizados que se dirigen al factor tisular humano.
TW202016144A (zh)	2018-06-21	2020-05-01	日商第一三共股份有限公司	包括cd3抗原結合片段之組成物及其用途
EP3924386A4 (en)	2019-02-13	2023-01-04	The Brigham & Women's Hospital, Inc.	ANTI-PERIPHERAL LYMPH NODE RESPONSIBLE ANTIBODIES AND USES THEREOF
CN113939534A (zh)	2019-04-03	2022-01-14	建新公司	具有降低的断裂的抗αβTCR结合多肽
CA3141492A1 (en)	2019-05-24	2020-12-03	Sanofi	Methods for treating systemic sclerosis
WO2021202463A1 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Anti-rsv antibodies
US20230382978A1 (en)	2020-10-15	2023-11-30	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
WO2022153194A1 (en)	2021-01-13	2022-07-21	Memorial Sloan Kettering Cancer Center	Antibody-pyrrolobenzodiazepine derivative conjugate
US20240115721A1 (en)	2021-01-13	2024-04-11	Memorial Sloan Kettering Cancer Center	Anti-dll3 antibody-drug conjugate
IL305301A (en)	2021-02-19	2023-10-01	Us Health	Single domain antibodies neutralizing SARS CoV-2

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1564666A (en) *	1978-05-31	1980-04-10	Ng Mun Hon	Heterocomplexes of interferon with immunoglobulin and pharmaceutical compositions thereof
GB2148299B (en) *	1983-09-01	1988-01-06	Hybritech Inc	Antibody compositions of therapeutic agents having an extended serum half-life
US4703004A (en) *	1984-01-24	1987-10-27	Immunex Corporation	Synthesis of protein with an identification peptide
US4590071A (en) *	1984-09-25	1986-05-20	Xoma Corporation	Human melanoma specific immunotoxins
DE3585778D1 (de) *	1984-12-05	1992-05-07	Salk Inst For Biological Studi	Monoklonaler antikoerper, spezifisch fuer brustkrebszelloberflaechenantigen.
NO881077L (no) *	1987-03-11	1988-09-12	Univ Michigan	Kjemo-radio-immuno-konjugater.
DE3879395T2 (de) *	1987-05-29	1993-06-24	Central Glass Co Ltd	Fusionsprotein, enthaltend lymphotoxin.
PH26813A (en) *	1987-09-02	1992-11-05	Ciba Geigy Ag	Conjugates of cytokines with immunoglobulins
CA1329119C (en) *	1988-03-29	1994-05-03	Milton David Goldenberg	Cytotoxic therapy
IE62463B1 (en) *	1988-07-07	1995-02-08	Res Dev Foundation	Immunoconjugates for cancer diagnosis and therapy

1990
- 1990-04-19 ZA ZA902949A patent/ZA902949B/xx unknown
- 1990-04-19 IE IE140590A patent/IE63847B1/en not_active IP Right Cessation
- 1990-04-20 CA CA002015060A patent/CA2015060C/en not_active Expired - Lifetime
- 1990-04-23 AU AU53795/90A patent/AU645747B2/en not_active Ceased
- 1990-04-23 NZ NZ233413A patent/NZ233413A/en unknown
- 1990-04-23 IL IL9416790A patent/IL94167A/xx not_active IP Right Cessation
- 1990-05-01 AT AT90304734T patent/ATE98873T1/de not_active IP Right Cessation
- 1990-05-01 ES ES90304734T patent/ES2060947T3/es not_active Expired - Lifetime
- 1990-05-01 JP JP11570990A patent/JP3589459B2/ja not_active Expired - Fee Related
- 1990-05-01 DK DK90304734.8T patent/DK0396387T3/da active
- 1990-05-01 DE DE90304734T patent/DE69005352T2/de not_active Expired - Fee Related
- 1990-05-01 EP EP90304734A patent/EP0396387B1/en not_active Expired - Lifetime
- 1990-05-04 FI FI902245A patent/FI100092B/fi active IP Right Grant
- 1990-05-04 PT PT93966A patent/PT93966B/pt not_active IP Right Cessation
- 1990-05-04 NO NO901986A patent/NO301168B1/no not_active IP Right Cessation
- 1990-05-04 KR KR1019900006320A patent/KR0181294B1/ko not_active IP Right Cessation
- 1990-05-05 CN CN90102690A patent/CN1072505C/zh not_active Expired - Lifetime
- 1990-10-16 SA SA90110099A patent/SA90110099B1/ar unknown
1998
- 1998-06-23 HK HK98106039A patent/HK1006678A1/xx unknown

Also Published As

Publication number	Publication date
SA90110099B1 (ar)	2004-02-15
NO901986L (no)	1990-11-06
CA2015060A1 (en)	1990-11-05
KR900017612A (ko)	1990-12-19
ES2060947T3 (es)	1994-12-01
DE69005352T2 (de)	1994-04-14
CN1072505C (zh)	2001-10-10
JPH02306923A (ja)	1990-12-20
FI100092B (fi)	1997-09-30
EP0396387A2 (en)	1990-11-07
KR0181294B1 (ko)	1999-03-20
NO901986D0 (no)	1990-05-04
CA2015060C (en)	2008-03-18
IL94167A0 (en)	1991-01-31
ATE98873T1 (de)	1994-01-15
JP3589459B2 (ja)	2004-11-17
HK1006678A1 (en)	1999-03-12
PT93966B (pt)	1996-12-31
IL94167A (en)	1997-02-18
AU5379590A (en)	1990-11-08
EP0396387B1 (en)	1993-12-22
IE901405L (en)	1990-11-05
EP0396387A3 (en)	1991-04-03
DE69005352D1 (de)	1994-02-03
IE63847B1 (en)	1995-06-14
AU645747B2 (en)	1994-01-27
CN1047035A (zh)	1990-11-21
ZA902949B (en)	1992-02-26
NZ233413A (en)	1992-05-26
PT93966A (pt)	1991-02-08
FI902245A0 (fi)	1990-05-04
DK0396387T3 (da)	1994-02-14

Legal Events

Date	Code	Title	Description
2010-05-10	MK1K	Patent expired

Publication	Publication Date	Title
NO301168B1 (no)	1997-09-22	Fremgangsmåte for fremstilling av et konjugat av et antistoff rettet mot antigen
AU636113B2 (en)	1993-04-22	Immunoconjugates for cancer diagnosis and therapy
US5744580A (en)	1998-04-28	Immunotoxins comprising ribosome-inactivating proteins
US6750329B1 (en)	2004-06-15	Antibody delivery system for biological response modifiers
Hirota et al.	1989	Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody
JP3340127B2 (ja)	2002-11-05	異常増殖性疾患措置のための抗体接合体
JP3949158B2 (ja)	2007-07-25	Ｃｄ３３関連表面抗原に対する免疫毒素